

Candidate development of anti-TCTP neutralizing candidate (BIO101) for the treatment of solid tumors

Boostimmune



| ONCOLOGY | Candidate |
|--------------------------|--|
| Product Type | Monoclonal antibody |
| Indication | Solid tumors |
| Target | Translationally controlled tumor protein (TCTP) |
| MoA(Mechanism of Action) | BIO101 inhibits MDSC in tumor microenvironment via neutralization of TCTP |
| Competitiveness | <ul style="list-style-type: none"> • First-in-class No companies that develop therapeutics for targeting MDSC are currently working on TCTP neutralization. The target is not only to contribute to MDSC recruitment and activity but also feasible to usable for biomarker. |
| Development Stage | Candidate |
| Route of Administration | Parenteral-Intravenous |